Abstract
Background Antibiotic stewardship in critically ill pneumonia patients is crucial yet challenging, partly due to the limited diagnostic yield of noninvasive infectious tests. In this study, we report an antibiotic prescription pattern informed by bronchoalveolar lavage (BAL) results, where clinicians de-escalate antibiotics based on the combination of quantitative cultures and multiplex PCR rapid diagnostic tests.
Methods We analyzed data from SCRIPT, a single-center prospective cohort study of mechanically ventilated patients who underwent a BAL for suspected pneumonia. We used the novel Narrow Antibiotic Therapy (NAT) score to quantify day-by-day antibiotic prescription pattern for each suspected pneumonia episode etiology (bacterial, viral, mixed bacterial/viral, microbiology-negative, and non-pneumonia control). We also analyzed and compared clinical outcomes for each pneumonia etiology, including unfavorable outcomes (a composite of in-hospital mortality, discharge to hospice, or requiring lung transplantation during hospitalization), duration of ICU stay, and duration of intubation. Clinical outcomes were compared with the Mann-Whitney U test and Fisher’s exact test.
Results We included 686 patients with 927 pneumonia episodes. NAT score analysis indicated that an antibiotic de-escalation pattern was evident in all pneumonia etiologies except resistant bacterial pneumonia. Microbiology-negative pneumonia was treated similarly to susceptible bacterial pneumonia in terms of antibiotic spectrum. Over a quarter of the time in viral pneumonia episodes, antibiotics were completely discontinued. Unfavorable outcomes were comparable across all pneumonia etiologies. Patients with viral and mixed bacterial/viral pneumonia had longer durations of ICU stay and intubation.
Conclusions BAL quantitative cultures and multiplex PCR rapid diagnostic tests resulted in prompt antibiotic de-escalation in critically ill pneumonia patients. There was no evidence of increased incidence of unfavorable outcomes.
Key points We found that bronchoalveolar lavage-based diagnostics is associated with antibiotic de-escalation, including to no antibiotics in more than a quarter of cases where only a virus is recovered.
Competing Interest Statement
Declarations of interests: BDS holds US patent 10,905,706, "Compositions and methods to accelerate resolution of acute lung inflammation," and serves on the scientific advisory board of Zoe Biosciences, in which he holds stock options. Other authors declare no conflicts of interest.
Funding Statement
SCRIPT is supported by NIH/NIAID U19AI135964. CAG is supported by NIH/NHLBI K23HL169815, a Parker B. Francis Opportunity Award, and an ATS Unrestricted Grant. BDS is supported by the NIH (R01HL149883, R01HL153122, P01HL154998, P01AG049665, and U19AI135964). RGW is supported by NIH grants U19AI135964, U01TR003528, P01HL154998, R01HL149883, R01LM013337. CIP is supported by NIAID (U19AI135964), Northwestern University Clinical and Translational Sciences Institute (5KL2TR001424-09). The funding sources did not have a role in the design, execution, or prior review of the study or in the data presented in this manuscript. Opinions expressed in this work do not necessarily reflect those of the funding sources.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Northwestern University Institutional Review Board with study ID STU00204868. Study participants or their surrogates provided informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
A significant portion of this data has been already made available through PhysioNet at https://physionet.org/content/script-carpediem-dataset/1.1.0/,[28] a future update will include new patients and updated data since the publication of the original dataset. Code is available at https://github.com/NUSCRIPT/mz_abx_deescalation_2024.
